GlassScriptPhysician profile
Jeffrey Bail Walker
NPI 1508250549
$12,264.10
in general payments reported to CMS, 2019-2025
55 companies · $2,790 in 2025
The $2,790 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2021: $756 · 2022: $2,878 · 2023: $2,518 · 2024: $3,122 · 2025: $2,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,314 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,314.35 |
| Education | $115.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,538.31 | 2021-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $1,344.51 | 2021-2025 | |
| Teleflex LLC | $1,030.66 | 2021-2025 | Urolift |
| Astellas Pharma US INC | $785.28 | 2021-2024 | Xtandi, Myrbetriq, Padcev |
| Urogen Pharma, INC. | $731.86 | 2021-2025 | Jelmyto |
| Pfizer INC. | $561.57 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $523.17 | 2023-2025 | Orgovyx, Gemtesa |
| Astrazeneca Pharmaceuticals LP | $506.83 | 2022-2025 | Lynparza, Imfinzi |
| Boston Scientific Corporation | $421.73 | 2019-2023 | Lithovue, Spaceoar Vue System - 10ml |
| Merck Sharp & Dohme LLC | $412.59 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Ferring Pharmaceuticals INC. | $334.23 | 2024-2025 | Adstiladrin |
| Procept Biorobotics Corporation | $324.02 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Medtronic, INC. | $303.08 | 2022-2024 | Interstim |
| Janssen Scientific Affairs, LLC | $287.25 | 2022-2025 | Erleada |
| 180 Medical, INC. | $223.52 | 2021-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.